Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Ulrike K. Buchwald, Charles P. Andrews, John Ervin, James T. Peterson, Gretchen M. Tamms, David Krupa, Patrick Ajiboye, Lucy Roalfe, Andrea L. Krick, Tina M. Sterling, Meihua Wang, Jason C. Martin, Jon E. Stek, Melvin A. Kohn, Temitope Folaranmi, Chitrananda Abeygunawardana, Jonathan Hartzel & Luwy K. Musey. (2021) Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older. Human Vaccines & Immunotherapeutics 17:8, pages 2678-2690.
Read now
Read now
Koji Kuronuma & Hiroki Takahashi. (2019) Immunogenicity of pneumococcal vaccines in comorbid autoimmune and chronic respiratory diseases. Human Vaccines & Immunotherapeutics 15:4, pages 859-862.
Read now
Read now
Andrew D. Wiese, Marie R. Griffin & Carlos G. Grijalva. (2019) Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States. Expert Review of Vaccines 18:4, pages 327-341.
Read now
Read now
John M. McLaughlin, David L. Swerdlow, Raul E. Isturiz & Luis Jodar. (2019) Decision-making for PCV in adults. Human Vaccines & Immunotherapeutics 15:3, pages 584-593.
Read now
Read now
Lander Willem, Adriaan Blommaert, Germaine Hanquet, Nancy Thiry, Joke Bilcke, Heidi Theeten, Jan Verhaegen, Herman Goossens & Philippe Beutels. (2018) Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium. Human Vaccines & Immunotherapeutics 14:5, pages 1218-1229.
Read now
Read now
Angel Vila-Corcoles, Olga Ochoa-Gondar, Imma Hospital, Cinta de Diego, Eva Satué, Jordi Bladé, Xabier Ansa, Jorge A. Guzmán, Elisabet Salsench & Francisca Ramos. (2016) Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia. Human Vaccines & Immunotherapeutics 12:11, pages 2953-2958.
Read now
Read now
Hans-Christian Slotved. (2016) Other age groups than children need to be considered as carriers of Streptococcal pneumoniae serotypes. Human Vaccines & Immunotherapeutics 12:10, pages 2670-2674.
Read now
Read now
A. T. Newall. (2016) What do we know about the cost-effectiveness of pneumococcal conjugate vaccination in older adults?. Human Vaccines & Immunotherapeutics 12:10, pages 2666-2669.
Read now
Read now
Articles from other publishers (12)
Jairam Meena, Robin Kumar, Mamta Singh, Anees Ahmed & Amulya Kumar Panda. (2020) Modulation of immune response and enhanced clearance of Salmonella typhi by delivery of Vi polysaccharide conjugate using PLA nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 152, pages 270-281.
Crossref
Crossref
Thijs W. HoffmanBob MeekGer T. RijkersJan C. GruttersDiana A. van Kessel. (2020) Pneumococcal Conjugate Vaccination Followed by Pneumococcal Polysaccharide Vaccination in Lung Transplant Candidates and Recipients. Transplantation Direct 6:6, pages e555.
Crossref
Crossref
Claire E. Gustafson, Chulwoo Kim, Cornelia M. Weyand & Jörg J. Goronzy. (2020) Influence of immune aging on vaccine responses. Journal of Allergy and Clinical Immunology 145:5, pages 1309-1321.
Crossref
Crossref
Angel Vila-Corcoles, Immaculada Hospital, Olga Ochoa-Gondar, Eva Satue, Cinta de Diego, Angel Vila-Rovira, Frederic Gómez-Bertomeu, Xavier Raga & María Aragón. (2020) Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015–2016. Vaccine 38:5, pages 1170-1180.
Crossref
Crossref
James P Phipps & Karen M Haas. (2019) An Adjuvant That Increases Protective Antibody Responses to Polysaccharide Antigens and Enables Recall Responses. The Journal of Infectious Diseases 219:2, pages 323-334.
Crossref
Crossref
Angel Vila-Corcoles, Olga Ochoa-Gondar, Cinta de Diego, Eva Satue, María Aragón, Angel Vila-Rovira, Frederic Gomez-Bertomeu, Ramon Magarolas, Enric Figuerola-Massana, Xavier Raga, Mar O. Perez & Frederic Ballester. (2018) Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study. BMC Infectious Diseases 18:1.
Crossref
Crossref
Olga Ochoa-Gondar, Ángel Vila-Córcoles, Cinta de Diego, Eva Satué, Angel Vila-Rovira & María Aragón. (2018) Vacunación antineumocócica en adultos de Cataluña: coberturas y grado de adecuación a distintas guías de recomendaciones. Atención Primaria 50:9, pages 553-559.
Crossref
Crossref
Mariëlle van Aalst, Annefleur C. Langedijk, René Spijker, Godelieve J. de Bree, Martin P. Grobusch & Abraham Goorhuis. (2018) The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis. Vaccine 36:39, pages 5832-5845.
Crossref
Crossref
O. Ochoa-Gondar, I. Hospital, A. Vila-Corcoles, M. Aragon, M. Jariod, C. de Diego & E. Satue. (2017) Prevalence of high, medium and low-risk medical conditions for pneumococcal vaccination in Catalonian middle-aged and older adults: a population-based study. BMC Public Health 17:1.
Crossref
Crossref
Heather L. Sings. (2017) Pneumococcal conjugate vaccine use in adults – Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia. Vaccine 35:40, pages 5406-5417.
Crossref
Crossref
Gili Regev-Yochay, Michal Katzir, Jacob Strahilevitz, Galia Rahav, Talya Finn, Dan Miron, Yasmin Maor, Bibiana Chazan, Yehudith Schindler & Ron Dagan. (2017) The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel. Vaccine 35:18, pages 2449-2456.
Crossref
Crossref
Ronald J. Stanek, Nancy B. Norton & Maurice A. Mufson. (2016) A 32-Year Study of the Effect of Pneumococcal Vaccines on Invasive Streptococcus pneumoniae Disease. The American Journal of the Medical Sciences 352:6, pages 563-573.
Crossref
Crossref